Analytical performance characteristics of the Abbott Architect i2000 Tacrolimus assay; comparisons with liquid chromatography-tandem mass spectrometry (LC-MS/MS) and Abbott IMx methods

Clinica Chimica Acta

Volumn 410, Issue 1-2, 2009, Pages 25-30

  De, Barun K ^a   Jimenez, E ^a   De, S ^a   Sawyer, J C ^b   McMillin, G A ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b ARUP LABORATORIES   (United States)

Author keywords

Drug monitoring; FK 506; Functional sensitivity; Method evaluation; Tacrolimus; Transplantation

Indexed keywords

TACROLIMUS;

ACCURACY; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; TANDEM MASS SPECTROMETRY;

ADULT; BIAS (EPIDEMIOLOGY); CHROMATOGRAPHY, LIQUID; DRUG MONITORING; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; LIMIT OF DETECTION; MALE; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; TACROLIMUS; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 70350567261     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.09.009     Document Type: Article

References (24)

1. Kino T., Hatanaka H., Hasimoto M., et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation and physico-chemical and biological characteristics. J Antibiot 40 (1987) 1249-1255
2. Wallemacq P.E., and Reding R. FK-506 (Tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical, and analytical aspects. Clin Chem 39 (1993) 2219-2228
3. Silverberg N.B., Lin P., Travis L., et al. Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases. J. Amer. Acad of Dermatol 51 5 (Nov 2004) 760-766
4. Jusko W.J., Thomson A.W., Fung J., et al. Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit 17 (1995) 606-614
5. Liu J., Farmer J., Lane W., Friedman J., Weissman I., and Schreiber S. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66 4 (1991) 807-815
6. Sawada S., Suzuki G., Kawase Y., and Takaku F. Novel immunosuppressive agent, FK506. In vivo effects from cloned T cell activation. J Immunol 139 (1987) 1797-1803
7. Fung J.J., Alessiani M., Abu-Elmagd K., et al. Adverse effects associated with the use of FK-506. Transplant Proc 23 6 (1991) 3105-3108
8. Jusko W.J., Peikoszewski W., Klintmalm G.B., et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 57 (1995) 281-290
9. Venkataramanan R., Jain A., Warty V.W., et al. Pharmacokinetics of FK506 following oral administration. A comparison of FK506 and cyclosporine. Transplant Proc 23 1 (1991) 931-933
10. Warty V., Zuckerman S., Venkataramanan R., et al. FK506 measurement: comparison of different analytical methods. Ther Drug Monit 15 3 (1993) 204-208
11. Vincent S.H., Karanam B.V., Painter S.K., and Chiu S.H.L. In vitro metabolism of FK - 506 in rat, rabbit and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism. Arch Biochem Biophys 294 (1992) 454-460
12. Sattler M., Guengerich F.P., Ung C.H., Christians U., and Sewing K.F. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metal Dispos 20 (1992) 753-761
13. Karanam B.V., Vincent S.H., and Chiu S.H.L. FK506 metabolism in human liver microsomes: investigation of the involvement of cytochrome P450 isozymes other than CYP3A4. Drug Metal Dispos 22 (1994) 811-814
14. Wallemacq P., Golfinet J., O'Morchoe S., et al. Analytical multi-site evaluation of the Abbott Architect Tacrolimus assay. 10th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology (September 9-14, 2007)
15. Abbott Laboratories, Diagnostics Division, Abbott Park, IL, IMx System, Tacrolimus II, Ref 3C10.
16. Streit F., Armstrong V.W., and Oellerich M. Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus and cyclosporine A in whole blood. Clin Chem 48 (2002) 955-958
17. Abbott Laboratories, Diagnostics Division, Abbott Park, IL, Architect System, Tacrolimus, Ref 1 L77.
18. Wallemacq P., Goffinet J., O'Morchoe S., et al. Multi-site analytical evaluation of the Abbott Architect Tacrolimus assay. Ther. Drug. Monit. 31 (2009) 198-204
19. Wallemacq P., Armstrong V.W., Brunet M., et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European Consensus Conference. Ther. Drug. Monit. 31 (2009) 139-152
20. Amann S., Parker T.S., and Levine D.M. Evaluation of 2 immunoassays for monitoring low blood levels of tacrolimus. Ther. Drug. Monit. 31 (2009) 273-276
21. Murthy J.N., Davis D.L., Yatscoff R.W., et al. Tacrolimus metabolite cross reactivity in different tacrolimus assays. Clin Biochem 31 (1998) 613-617
22. Goffinet J.S., Mullier F., Capron A., et al. Evaluation of three immunoassays to quantify tacrolimus: impact of hematocrit (Abstract). Ther Drug Monit. 29 (2007) 508
23. Conti D.J., Petrov R., Elbalhoul O., and Gallichio M. Sirolimus-based, calcineurin-inhibitor sparing immunotherapy, long-term (6-year) results. Transplant Immunology 20 (2008) 12-13
24. Ekberg H., Tedesco-Silva H., Demirbas A., et al. The ELITE-Symphony study. Reduced exposure to calcineurin inhibitors in renal transplantation. N. Engl. J. Med. 357 (2007) 2562-2575